Madrigal Pharmaceuticals, Inc.
MDGL
株式のランク
#2014
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
株価
$446.50
最終同期: 2026-10-19
時価総額
$10.32B
変化（1日）
-0.72%
変化（1年）
1.48%
国
US
取引 Madrigal Pharmaceuticals, Inc. (MDGL)
カテゴリー
Healthcare
Madrigal Pharmaceuticals, Inc.（MDGL）の利益
Jun 2026 時点の利益 TTM: $-325.10M
Madrigal Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は $-325.10M です。2023 年には $-373.63M の利益を上げ、これは 2022 年の利益 $-295.35M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Madrigal Pharmaceuticals, Inc. の利益の推移（2001 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-325.10M | -30.22% |
| 2024 | $-465.89M | 24.69% |
| 2023 | $-373.63M | 26.50% |
| 2022 | $-295.35M | 22.12% |
| 2021 | $-241.85M | 19.58% |
| 2020 | $-202.24M | 140.92% |
| 2019 | $-83.95M | 155.85% |
| 2018 | $-32.81M | 5.32% |
| 2017 | $-31.15M | 18.06% |
| 2016 | $-26.39M | -61.57% |
| 2015 | $-68.67M | -20.30% |
| 2014 | $-86.16M | -4.47% |
| 2013 | $-90.19M | 43.64% |
| 2012 | $-62.79M | 32.52% |
| 2011 | $-47.38M | 26.46% |
| 2010 | $-37.47M | -147.37% |
| 2009 | $79.09M | -185.39% |
| 2008 | $-92.62M | 45.87% |
| 2007 | $-63.50M | 7.38% |
| 2006 | $-59.13M | -14.14% |
| 2005 | $-68.86M | 49.92% |
| 2004 | $-45.93M | 64.77% |
| 2003 | $-27.88M | -48.71% |
| 2002 | $-54.35M | 0.00% |
| 2001 | 0.00 | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -1,722.57% |
US
|
|
| $-3.09B | 849.57% |
US
|
|
| $-4.02B | 1,135.39% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -700.02% |
NL
|
